Search

Displaying results 1331 - 1340 of 10000 in total
  1. Drug

    Rilzabrutinib

    go.drugbank.com/drugs/DB17709
    ApprovedInvestigational

    [L53743] ITP is an autoimmune disorder characterized by low platelet count. … Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune

    Synonyms: (e/z)-(r)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)piperidine-1-carbonyl)-4-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)pent-2-enenitrile
  2. Drug

    Tremelimumab

    go.drugbank.com/drugs/DB11771
    ApprovedInvestigational

    [A253717, L43652] Because CTLA-4 is an immune checkpoint that plays a vital role in regulating T cell-mediated immune response, tremelimumab is considered an immune checkpoint inhibitor, which is an emerging … [A253712] Tremelimumab was first approved by the FDA in October 2022 to be used in combination with [durvalumab] to treat hepatocellular carcinoma.

  3. Drug

    Nicotine

    go.drugbank.com/drugs/DB00184
    ApprovedInvestigational

    Nicotine is also important medically because of its presence in tobacco smoke.

    Synonyms: 3-(N-methylpyrollidino)pyridine, 3-(2-(N-methylpyrrolidinyl))pyridineCategories: Drugs Used in Addictive Disorders, Drugs Used in Nicotine Dependence
  4. Drug

    Tetraferric tricitrate decahydrate

    go.drugbank.com/drugs/DB14520
    ApprovedInvestigational

    Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. … [A25965] Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014.[L9926]

  5. Drug

    Molybdenum

    go.drugbank.com/drugs/DB11137
    ApprovedInvestigational

    As it is not a naturally occuring free metal on Earth, molybdenum is found only in various oxidation states in minerals. … It is an essential trace dietary element and acts as a critical cofactor in several molybdenum-dependent enzymes that are involved in important cellular reactions and pathways, including xanthine oxidoreductase

    Mixtures: Ribotin-E, ADDAMEL N
  6. Drug

    Calcium polycarbophil

    go.drugbank.com/drugs/DB14684
    Approved

    It is insoluble in water, dilute acids, and dilute alkali. … Based on its chemical structure, it is a synthetic polymer of polyacrylic acid cross-linked with divinyl glycol presenting a calcium atom as a counter-ion.

    Categories: Compounds used in a research, industrial, or household settingProducts: Fiber-ON-tablet
  7. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist

  8. Drug

    Pentastarch

    go.drugbank.com/drugs/DB09111
    ApprovedWithdrawn

    Pentastarch is an artificial colloid (hydroxyethyl starch derivative). Pentastarch is characterized by presenting five hydroxyethyl groups, which signifies an approximate 50% hydroxyethylation. … When administered, pentastarch remains mainly in the circulatory system and hence, it is considered a plasma expander.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Insulin glulisine

    go.drugbank.com/drugs/DB01309
    Approved

    Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able … As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin glulisine, to lower glucose levels in the blood.

    Categories: Drugs Used in DiabetesProducts: Apidra SoloStar 100 Units/ml Solution for injection in a pre-filled pen, APIDRA SOLOSTAR 100 UNITS/ML, SOLUTION FOR INJECTION IN A PRE-FILLED PEN
  10. Drug

    Rilpivirine

    go.drugbank.com/drugs/DB08864
    ApprovedInvestigational

    [L1031] Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021. … [L31193] While previously administered once-monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in

    Synonyms: 4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrileCategories: Antivirals used in combination for the treatment of HIV infections